Biggest News Aggregation in the World
📰 Pilot Edition News

Pilot Edition News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Pilot Edition. Real-time updates on events, politics, business and more.

Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Ro...

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in ChinaThe amu...
United States Brii Bio Rogers Luo Therapeutics Beijing Co Ltd China Resources Pharmaceutical Group National Health Commission Of China

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections in China Clinical benefits were observed in efficacy indicators such as RNAconversion rate, resolutionofCOVID-19 symptoms, and riskof progressing to severe disease DURHAM, N.C. and BEIJING, June 9, 2022 /PRNewswire/ --Brii Biosciences Limited("Brii Bio" or the "Company", stock code: ...
United States Nanshan Zhong Brii Bio Rogers Luo Therapeutics Beijing Co Ltd National Health Commission Of China

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China - read this article along with other careers information, tips and advice on BioSpace
United States Hong Kong Yong Liu Brii Bio Rogers Luo Sinopharm Holding Co Ltd

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

DURHAM, N.C. and BEIJING, March 29, 2022 /PRNewswire/ -- Brii Biosciences Limited a multi-national company developing innovative therapies for diseases with significant unmet medical needs and... | April 3, 2022
United States Hong Kong Yong Liu Brii Bio Rogers Luo Sinopharm Holding Co Ltd

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for...
United States Yong Liu Brii Bio Rogers Luo Sinopharm Holding Co Ltd Therapeutics Beijing Co Ltd

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science